NCT05461261View on ClinicalTrials.gov

The Efficacy and Safety of Docetaxel Combined With Platinum for Metastatic Hormone-sensitive Prostate Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

July 1, 2022

Primary Completion Date

June 30, 2025

Study Completion Date

December 31, 2025

Conditions
Hormone Sensitive Metastatic Prostate CancerDNA Damage Repair DeficiencyChemotherapy EffectChemotherapeutic Toxicity
Interventions
DRUG

Docetaxel

Docetaxel will be given intravenously 75 mg/m2 every 3 weeks for 6 cycles.

DRUG

Prednisolone Acetate

5mg Prednisolone Acetate will be given orally twice a day during treatment.

DRUG

Platinum-based drugs

Platinum-based drugs will be given intravenously 70 mg/m2 every 3 weeks for 6 cycles. Cisplatin or carboplatin will be carefully chosen according to each patient's Creatinine Clearance.

Trial Locations (1)

210000

RECRUITING

Department of Urology, Drum Tower Hospital, Medical School of Nanjing University, Institute of Urology, Nanjing University, Nanjing

All Listed Sponsors
lead

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

OTHER